Harvard Bioscience (HBIO) Cost of Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has reported Cost of Revenue for 17 consecutive years, with $235000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 97.55% year-over-year to $235000.0; the TTM figure through Mar 2026 stood at -$25.9 million (down 187.41% YoY), while the FY2025 annual figure was $729000.0, down 98.15% from the prior year.
• Cost of Revenue improved to $235000.0 in Q1 2026 per HBIO's latest filing, from -$26.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $14.8 million in Q3 2022 and bottomed at -$26.3 million in Q4 2025.
• Historically, Cost of Revenue has averaged $5.3 million across 5 years, with a median of $9.6 million in 2025.
• On a YoY basis, Cost of Revenue climbed as much as 892.75% in 2025 and fell as far as 349.86% in 2025.
• Harvard Bioscience's Cost of Revenue stood at $12.6 million in 2022, then retreated by 6.08% to $11.8 million in 2023, then decreased by 10.85% to $10.5 million in 2024, then tumbled by 349.86% to -$26.3 million in 2025, then jumped by 100.89% to $235000.0 in 2026.
• Business Quant data shows HBIO's Cost of Revenue at $235000.0 in Q1 2026, -$26.3 million in Q4 2025, and $48000.0 in Q3 2025.